中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 2
Feb.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(2): 271-277

Efficacy and safety of sofosbuvir/velpatasvir alone or in combination with ribavirin in treatment of patients with genotype 3B HCV/HIV infection

DOI: 10.12449/JCH240209
  • 1.

    Yunnan Provincial Clinical Medical Center for Infectious Diseases，The Third People’s Hospital of Kunming，Kunming 650041，China

  • 2.

    Department of Infectious Diseases，The First People’s Hospital of Zaoyang，Zaoyang，Hubei 430000，China

Research funding:

Scientific Research Special Fund of YouAn College Union (LM202014)

More Information
  • Corresponding author: LI Junyi， 759725784@qq.com （ORCID： 0000-0002-0813-3989）; LIU Chunyun， 751440760@qq.com （ORCID： 0000-0001-5343-5305）
  • Received Date: 2023-05-16
  • Accepted Date: 2023-07-27
  • Published Date: 2024-02-19
    Abstract
  •   Objective  To investigate the efficacy and safety of sofosbuvir/velpatasvir alone or in combination with ribavirin in Chinese patients with genotype 3B HCV/HIV infection.  Methods  A total of 299 patients with genotype 3B HCV/HIV infection who attended The Third People’s Hospital of Kunming from January 2017 to December 2020 were enrolled and treated with sofosbuvir/velpatasvir alone or in combination with ribavirin for 12 weeks， and they were followed up for 12 weeks after drug withdrawal. The patients were evaluated in terms of sustained virologic response at 12 weeks after treatment （SVR12） and adverse reactions. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups， and the chi-square test was used for comparison of categorical data between two groups； the Agresti-Coull method was used to evaluate the 95% confidence interval （CI） of SVR12； univariate and multivariate non-conditional logistic regression analyses were used to investigate the influencing factors for SVR.  Results  The 299 patients with genotype 3B HCV/HIV infection had a mean age of 43.92±6.84 years， among whom the male patients accounted for 77.3% （231/299）， the patients with liver cirrhosis accounted for 36.5% （109/299）， the patients with a history of antiviral therapy accounted for 13.4% （40/299）， and the patients receiving sofosbuvir/velpatasvir combined with ribavirin accounted for 27.8% （83/299）. The overall SVR was 87.0% （260/299） for all patients， and there was no significant difference in SVR12 between the patients receiving sofosbuvir/velpatasvir alone and those receiving sofosbuvir/velpatasvir combined with ribavirin （87.5% vs 85.5%， χ2=0.203， P=0.653）. There was a significant difference in SVR12 between the patients without liver cirrhosis and those with liver cirrhosis （90.0% vs 81.7%， χ2=4.256， P=0.039）， and the patients receiving antiviral therapy for the first time had a significantly higher SVR12 than the treatment-experienced patients （93.4% vs 45.0%， χ2=71.670， P<0.001）. The univariate and multivariate logistic regression analyses showed that platelet count （odds ratio ［OR］=0.957， 95%CI： 0.931 — 0.984， P=0.002）， liver stiffness measurement （OR=1.446， 95%CI： 1.147 — 1.822， P=0.002）， and experience in treatment （OR=13.807， 95%CI： 2.970 — 64.174， P=0.001） were independent influencing factors for SVR in patients with genotype 3B HCV/HIV infection. There were 41 cases of serious adverse events， all of which occurred within 2 weeks after antiviral therapy， and 28 cases were resolved without drug withdrawal or active treatment， while 13 cases were not resolved after active treatment and were resolved after the antiviral drugs were stopped for 2‍ ‍—‍ ‍5 days， with no similar reactions observed when the drugs were used again after remission.  Conclusion  Sofosbuvir/velpatasvir alone or in combination with ribavirin has relatively good efficacy and safety in patients with genotype 3B HCV/HIV infection.

     

    • FullText(HTML)
  • loading
    • References(13)
  • [1]
    World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[M]. Geneva: World Health Organization, 2018.
    [2]
    World Health Organization. Global hepatitis report[R]. Geneva: WHO, 2017.
    [3]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35( 12): 2670- 2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2670- 2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
    [4]
    XU AQ, ZHANG L. The review and significance of national seroepidemiological surveys on viral hepatitis in China[J]. Chin J Prevent Med, 2017, 51( 6): 457- 461. DOI: 10.3760/cma.j.issn.0253-9624.2017.06.001.

    徐爱强, 张丽. 中国病毒性肝炎血清流行病学调查的回顾与意义[J]. 中华预防医学杂志, 2017, 51( 6): 457- 461. DOI: 10.3760/cma.j.issn.0253-9624.2017.06.001.
    [5]
    YANG YQ, SHANG J, LU CZ, et al. Influencing factors for direct-acting antiviral therapy failure in treatment of hepatitis C[J]. J Clin Hepatol, 2022, 38( 5): 1059- 1063. DOI: 10.3969/j.issn.1001-5256.2022.05.016.

    杨宇晴, 尚佳, 卢诚震, 等. 直接抗病毒药物治疗丙型肝炎失败的影响因素分析[J]. 临床肝胆病杂志, 2022, 38( 5): 1059- 1063. DOI: 10.3969/j.issn.1001-5256.2022.05.016.
    [6]
    HE QF, HU R, ZENG YL, et al. Efficacy and safety of Sofosbuvir/Velpatasvir with or without ribavirin in treatment of patients with chronic hepatitis C virus genotype 3 infection: A real-world study[J/CD]. Chin J Liver Dis(Electronic Version), 2022, 14( 1): 6- 13. DOI: 10.3969/j.issn.1674-7380.2022.01.002.

    贺秋凤, 胡蓉, 曾义岚, 等. 索磷布韦/维帕他韦联合或不联合利巴韦林治疗基因3型慢性丙型肝炎病毒感染者的疗效及安全性: 一项真实世界研究[J/CD]. 中国肝脏病杂志(电子版), 2022, 14( 1): 6- 13. DOI: 10.3969/j.issn.1674-7380.2022.01.002.
    [7]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [8]
    GAYAM V, HOSSAIN MR, KHALID M, et al. Real-world clinical efficacy and tolerability of direct-acting antivirals in hepatitis C monoinfection compared to hepatitis C/human immunodeficiency virus coinfection in a community care setting[J]. Gut Liver, 2018, 12( 6): 694- 703. DOI: 10.5009/gnl18004.
    [9]
    MACHADO SM, VIGANI AG, LEITE AG, et al. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study[J]. Medicine, 2020, 99( 30): e21270. DOI: 10.1097/MD.0000000000021270.
    [10]
    TANG Q, WEI L, LIU XQ, et al. Sofosbuvir-based therapies achieved satisfactory virological response in Chinese individuals with genotypes 3 and 6 infections: A real-world experience[J]. Infect Drug Resist, 2021, 14: 2297- 2307. DOI: 10.2147/IDR.S312902.
    [11]
    ATSUKAWA M, TSUBOTA A, KONDO C, et al. Real-world clinical application of 12-week sofosbuvir/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: A prospective, multicenter study[J]. Infect Dis Ther, 2020, 9( 4): 851- 866. DOI: 10.1007/s40121-020-00329-y.
    [12]
    MANGIA A, MILLIGAN S, KHALILI M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts[J]. Liver Int, 2020, 40( 8): 1841- 1852. DOI: 10.1111/liv.14537.
    [13]
    JI FP, LI J, LIU L, et al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b[J]. J Gastroenterol Hepatol, 2021, 36( 3): 767- 774. DOI: 10.1111/jgh.15192.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (186) PDF downloads(46) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return